Alkermes plc. (ALKS)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10Sep'10
REVENUES:
Total revenues

1,194,065

1,170,947

1,073,979

1,067,456

1,092,226

1,094,274

1,053,882

1,022,547

936,746

903,374

841,518

804,374

780,698

745,694

695,278

667,690

623,895

628,335

640,398

647,737

649,791

618,789

598,106

577,916

563,123

596,333

577,764

561,940

575,548

542,599

532,333

480,333

389,977

303,479

227,083

0

0

0

EXPENSES:
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)

182,235

180,385

183,020

180,111

177,305

176,420

165,810

162,454

158,812

154,748

151,198

150,600

144,823

132,122

131,956

130,306

126,726

138,989

150,566

164,095

176,967

175,832

172,356

170,444

173,145

182,297

178,319

174,387

170,466

173,552

177,390

153,429

127,578

89,361

60,520

0

0

0

Research and development

503,542

512,833

423,648

417,242

419,630

425,406

420,924

424,070

416,400

412,889

398,025

393,058

390,911

387,148

391,208

384,322

375,198

344,404

325,151

310,856

290,181

272,043

246,326

214,010

180,265

163,925

146,528

135,669

140,013

149,403

158,577

151,649

141,893

119,206

102,645

0

0

0

Selling, general and administrative

591,601

599,449

586,223

566,299

549,481

526,408

496,077

466,933

437,626

421,578

407,827

399,339

386,510

374,130

364,457

362,809

338,227

311,558

278,890

241,281

220,405

199,905

189,272

176,838

159,108

151,237

136,933

128,907

125,758

125,511

131,113

135,919

137,632

123,721

106,688

0

0

0

Amortization of acquired intangible assets

40,176

40,400

46,645

52,898

59,083

65,200

64,425

63,642

62,867

62,100

61,740

61,420

61,105

60,959

59,842

58,726

57,621

57,685

58,723

59,760

60,797

58,153

55,765

53,377

51,004

48,750

46,443

44,134

41,852

43,426

34,694

0

-

0

0

-

-

-

Restructuring expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

Impairment of long-lived assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

Total expenses

1,330,913

1,346,426

1,239,504

1,216,518

1,205,467

1,193,402

1,147,195

1,117,058

1,075,664

1,051,274

1,018,790

1,004,417

983,349

954,359

947,463

936,163

897,772

852,636

813,330

775,992

748,350

705,933

663,719

614,669

563,522

561,855

523,869

498,743

493,735

537,438

557,399

522,586

478,258

346,001

271,670

0

0

0

OPERATING LOSS

-136,848

-175,479

-165,525

-149,062

-113,241

-99,128

-93,313

-94,511

-138,918

-147,900

-177,272

-200,043

-202,651

-208,665

-252,185

-268,473

-273,877

-224,301

-172,932

-128,255

-98,559

-87,144

-65,613

-36,753

-399

34,478

53,895

63,197

81,813

5,161

-25,066

-42,253

-88,281

-42,522

-44,587

0

0

0

OTHER INCOME (EXPENSE), NET:
Interest income

13,166

13,976

14,077

13,129

11,323

9,238

7,308

5,920

5,191

4,649

4,122

3,861

3,684

3,752

3,927

3,880

3,681

3,330

2,912

2,593

2,121

1,972

1,635

1,384

1,222

882

782

703

841

951

1,146

1,313

1,516

1,885

2,208

0

0

0

Interest expense

12,958

13,601

13,883

13,844

13,450

15,437

15,151

14,934

14,731

12,008

13,712

13,958

14,358

14,889

13,312

13,262

13,254

13,247

13,261

13,292

13,362

13,430

13,531

13,652

13,735

21,852

23,121

42,292

48,994

47,979

50,837

0

-

0

0

-

-

0

Change in the fair value of contingent consideration

6,600

-22,800

-30,100

-27,200

-40,300

-19,600

-11,600

-2,200

18,100

21,600

20,700

6,100

7,600

7,900

4,300

6,800

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on the Gainesville Transaction

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of property, plant and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of investment in Acceleron Pharma Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense, net

1,911

848

-759

815

-4,553

-2,040

-1,734

-10,722

-7,324

-9,615

-12,211

-3,885

-4,233

-2,485

-1,958

-577

475

15

1,036

-514

-581

-2,220

-2,043

-1,591

-2,279

-245

-504

688

1,781

1,311

1,705

1,318

484

687

260

0

0

0

Total other income (expense), net

8,719

-21,577

-30,665

-27,100

-46,980

-27,839

-21,177

-21,936

1,236

4,626

-1,101

-7,882

-7,307

-5,722

-10,682

-7,072

3,000

296

62,500

59,410

74,971

73,115

13,678

13,722

-14,792

-21,215

-22,843

-40,901

-46,372

-45,351

-50,517

-35,650

-26,111

-15,447

-7,261

0

0

0

LOSS BEFORE INCOME TAXES

-128,129

-197,056

-196,190

-176,162

-160,221

-126,967

-114,490

-116,447

-137,682

-143,274

-178,373

-207,925

-209,958

-214,387

-262,867

-275,545

-270,877

-224,005

-110,432

-68,845

-23,588

-14,029

-51,935

-23,031

-15,191

13,263

31,052

22,296

35,441

-40,190

-75,583

-77,903

-114,392

-57,969

-51,848

0

0

0

INCOME TAX PROVISION (BENEFIT)

10,747

-436

4,789

6,383

12,983

12,344

24,897

24,772

13,887

14,671

-9,076

-12,217

-10,056

-5,943

-6,182

-532

3,052

3,158

16,835

17,363

12,776

16,032

-9,437

-12,727

-8,486

-7,385

12,223

12,412

10,458

1,183

-3,124

104

-714

3,735

2,694

0

0

0

NET LOSS

-138,876

-196,620

-200,979

-182,545

-173,204

-139,311

-139,387

-141,219

-151,569

-157,945

-169,297

-195,708

-199,902

-208,444

-256,685

-275,013

-273,929

-227,163

-127,267

-86,208

-36,364

-30,061

-42,498

-10,304

-6,705

20,648

18,829

9,884

24,983

-41,373

-72,459

-78,007

-113,678

-61,704

-54,542

0

0

0

LOSS PER ORDINARY SHARE:
Basic and diluted (in dollars loss per ordinary share)

-0.24

-0.02

-0.34

-0.27

-0.62

-0.07

-0.22

-0.21

-0.40

-0.06

-0.24

-0.28

-0.45

-0.15

-0.41

-0.31

-0.51

-0.46

-0.54

-0.31

-0.21

-

-0.27

-

-0.17

-

-

-

-

-

-

-

-

-

-

-0.14

-

-

Basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.03

-

0.14

-0.06

0.05

0.02

0.12

-0.13

0.17

-

-0.11

-0.22

-

-0.12

-0.08

Diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.02

-

0.13

-0.06

0.05

0.02

0.12

-0.13

0.17

-

-0.11

-0.22

-

-

-

WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:
Basic and diluted (in shares)

158,095

157,678

157,199

156,991

156,336

155,520

155,328

155,176

154,424

153,880

153,684

153,392

152,704

152,158

151,652

151,301

150,825

150,356

149,512

148,867

148,089

-

145,896

-

143,358

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

144,913

-

137,172

136,106

134,602

133,272

132,097

131,067

130,434

130,015

129,670

102,474

96,649

95,667

95

Diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

154,300

-

155,408

136,106

143,369

139,677

137,497

131,067

134,945

130,015

129,670

102,474

96,649

-

-

COMPREHENSIVE LOSS:
Net loss

-138,876

-196,620

-200,979

-182,545

-173,204

-139,311

-139,387

-141,219

-151,569

-157,945

-169,297

-195,708

-199,902

-208,444

-256,685

-275,013

-273,929

-227,163

-127,267

-86,208

-36,364

-30,061

-42,498

-10,304

-6,705

20,648

18,829

9,884

24,983

-41,373

-72,459

-78,007

-113,678

-61,704

-54,542

0

0

0

Unrealized gain, net of a tax provision of $87 and $229, respectively

1,011

1,464

2,028

2,366

1,618

512

-414

-645

-926

-518

-445

-789

-341

522

-95

180

-215

-661

154

-14

4,606

1,586

6,849

15,509

10,561

13,235

8,375

0

0

0

-

-

627

-148

278

0

0

0

Unrealized losses on derivative contracts, net of tax of none, none and $(194), respectively

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

Reclassification of unrealized gains to realized gains

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gains (losses) on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-327

-211

-318

-43

627

-148

278

0

0

0

Unrealized gains on derivative contracts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

522

489

245

0

-

0

0

-

-

-

COMPREHENSIVE LOSS

-137,865

-195,156

-198,951

-180,179

-171,586

-138,799

-139,801

-141,864

-152,495

-158,463

-169,742

-196,497

-200,243

-207,922

-256,780

-274,833

-274,144

-227,824

-127,113

-86,222

-47,054

-43,771

-50,945

-10,091

3,856

33,883

27,204

9,884

25,178

-41,112

-72,338

-78,449

-113,378

-62,129

-54,508

0

0

0

Product sales, net
Total revenues

554,744

524,499

507,540

484,801

457,973

450,334

421,625

399,271

378,220

362,834

338,344

314,465

283,228

256,146

219,511

187,612

167,265

149,028

135,896

123,795

108,218

94,160

85,085

78,510

74,294

71,841

67,149

63,114

58,107

54,495

49,175

43,870

41,184

37,899

33,771

0

0

0

Manufacturing and royalty revenues
Total revenues

455,218

447,882

508,017

520,645

520,989

526,675

497,953

504,219

505,230

505,308

500,412

487,985

495,767

487,247

472,753

476,575

452,703

475,288

499,180

517,136

534,340

516,876

506,354

492,897

482,319

517,958

503,552

492,308

510,900

474,666

469,172

415,884

326,444

251,691

181,534

0

0

0

Research and development revenue
Total revenues

38,316

52,816

57,296

60,884

64,888

68,895

58,054

42,807

25,296

7,232

2,762

1,924

1,703

2,301

3,014

3,503

3,927

4,019

5,322

6,806

7,233

7,753

6,667

6,509

6,510

6,534

7,063

6,518

6,541

13,438

13,986

20,579

22,349

13,889

11,778

0

0

0

License revenue
Total revenues

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-